Hypercalcemia of Malignancy in Adults

Publication Date: December 20, 2022

Key Points

Key Points

  • Hypercalcemia of malignancy (HCM), a condition associated with high morbidity and mortality, is the most common metabolic complication of malignancies.
  • All adults with HCM should receive treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP).
  • Adults with calcitriol-mediated HCM should first be treated with glucocorticoids, with the addition of Dmab or an IV BP if glucocorticoid therapy is insufficient.

Treatment

...eatmen...

...ation 1In adults with HCM, Endocrine Society (ES...

...ecommendation 2In adults with HCM, ES su...

...ommendation 3In adults with severe HCM (serum cal...

...ion 4In adults with refractory/recurrent HCM o...

...dation 5In adults with HCM from tu...

...ommendation 6In adult patients with hyper...

...7In adult patients with hypercalcemia due...

...on 8In adult patients with hypercalcemia due to...


...actice Statements...

...adults with HCM, adequate hydration wit...

...s with HCM, dental hygiene and oral health...

...with HCM who receive antiresorptive therapy, vitam...

...with HCM, renal function (creatinine clearan...

...lts with HCM and renal insufficiency (defined...

...with HCM, serum magnesium and phos...

...adults with HCM, clinical oncology consul...

...with hypercalcemia due to parathyroid ca...


Table 1. Treatment Regimens for Hypercal...


...igure 1. Suggested Workflow for the Management of...


...Common Terminology Criteria for A...